Formulation of Aceclofenac Tablets Using Nanosuspension as Granulating Agent: An Attempt to Enhance Dissolution Rate and Oral Bioavailability.
enhanced oral bioavailability
nanosuspension-based tablets
release kinetics
Journal
International journal of nanomedicine
ISSN: 1178-2013
Titre abrégé: Int J Nanomedicine
Pays: New Zealand
ID NLM: 101263847
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
07
2020
accepted:
07
10
2020
entrez:
25
11
2020
pubmed:
26
11
2020
medline:
22
12
2020
Statut:
epublish
Résumé
The aim of the studies was to fabricate aceclofenac (AC) tablets using nanosuspension as granulating fluid to boost its rate of in vitro dissolution and eventually its oral bioavailability. The optimized nanosuspension with particle size of 112±2.01 nm was fabricated using HPMC 1% (w/v), PVP-K30 1% (w/v) and SLS 0.12% (w/v) at 400 watts of ultrasonication energy for 15 min duration and 3 sec pause. Then, the optimized aceclofenac nanosuspension was used as granulating fluid for aceclofenac tablets formulation. The characterization was performed using Malvern zetasizer, SEM, TEM, DSC and P-XRD. The granules were evaluated for the bulk and tapped densities, Hausner's ratio, angle of repose and their resulted values were found within limit. The prepared tablets were tested for average weight, hardness, friability, disintegration, dissolution and in vivo bioavailability in rabbits. The in vitro dissolution data showed the boosted rate of nanosuspension-based tablets compared to the microsuspension-based tablets. The in vivo bioavailability (in rabbits model) of aceclofenac nanosuspension-based tablets (ACN-1, ACN-2) proved an improved absorption as in comparison to the marketed formulation. The C This boosted in vitro and in vivo bioavailability may be attributed to reduced particle size of aceclofenac nanoformulations used in tablets. Finally, this will result in faster absorption of these fabricated tablets.
Identifiants
pubmed: 33235448
doi: 10.2147/IJN.S270746
pii: 270746
pmc: PMC7680606
doi:
Substances chimiques
Suspensions
0
Tablets
0
Diclofenac
144O8QL0L1
aceclofenac
RPK779R03H
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8999-9009Informations de copyright
© 2020 Rahim et al.
Déclaration de conflit d'intérêts
Umar Farooq is an employee of Legacy Pharmaceutical (Pvt.) Ltd. The authors report no other potential conflicts of interest for this work.
Références
Pharmaceutics. 2018 Jul 08;10(3):
pubmed: 29986543
Pak J Pharm Sci. 2015 May;28(3):909-14
pubmed: 26004724
Drug Discov Today. 2018 Mar;23(3):534-547
pubmed: 29326082
Int J Nanomedicine. 2013;8:3119-28
pubmed: 23983465
AAPS PharmSciTech. 2003 Dec 12;4(4):E61
pubmed: 15198556
Pharm Res. 2008 Oct;25(10):2334-44
pubmed: 18560998
Int J Pharm. 2006 Aug 31;320(1-2):23-9
pubmed: 16759826
Int J Pharm. 2014 Oct 20;474(1-2):146-50
pubmed: 25138256
Res Pharm Sci. 2015 Mar-Apr;10(2):95-108
pubmed: 26487886
J Control Release. 2011 Jan 20;149(2):175-81
pubmed: 20946923
Int J Pharm. 2008 Feb 28;350(1-2):279-90
pubmed: 17945447
J Colloid Interface Sci. 2008 Sep 15;325(2):404-13
pubmed: 18561941
Ultrason Sonochem. 2007 Sep;14(6):717-24
pubmed: 17254828
AAPS PharmSciTech. 2008;9(1):250-8
pubmed: 18446489
ILAR J. 1997;38(1):41-48
pubmed: 11528046
Eur J Pharm Sci. 2013 Jul 16;49(4):565-77
pubmed: 23587645
Eur J Pharm Biopharm. 2006 Jun;63(2):173-5
pubmed: 16621482
Toxicol Pathol. 2008 Jan;36(1):43-8
pubmed: 18337220
J Pharm Pharmacol. 2004 Jul;56(7):827-40
pubmed: 15233860
Drug Dev Ind Pharm. 2004 May;30(5):525-34
pubmed: 15244088
Int J Nanomedicine. 2019 Aug 06;14:6287-6296
pubmed: 31496686
Drug Des Devel Ther. 2019 Nov 28;13:4007-4020
pubmed: 31819372
Eur J Pharm Sci. 2010 Jul 11;40(4):325-34
pubmed: 20417274
Drug Des Devel Ther. 2017 Aug 23;11:2443-2452
pubmed: 28860715